Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALVAC HIV

Next Previous
X
Search
Drug Profile

ALVAC HIV

Alternative Names: ALVAC-HIV; ALVAC-HIV-vCP2438; HVTN702; vCP2438

Latest Information Update: 02 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi Pasteur
  • Developer GSK; Sanofi
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III HIV-1 infections

Most Recent Events

  • 21 Nov 2021 National Institute of Allergy and Infectious Diseases completes the phase IIb/III Uhambo trial in HIV-1 infections (Prevention) in South Africa (IM) (NCT02968849)
  • 03 Feb 2020 National Institute of Allergy and Infectious Diseases stops the phase IIb/III Uhambo trial in HIV-1 infections (Prevention) in South Africa as the vaccine did not prevent HIV (NCT02968849)
  • 12 Dec 2019 National Institute of Allergy and Infectious Diseases completes a phase I/II trial in HIV-1 infections (Prevention) in Mozambique, Zimbabwe, South Africa (IM) (NCT03284710)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top